Brief: Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program
21/02/2025 14:08
Feb 21 (Reuters) - Neurocrine Biosciences Inc NBIX.O :
* NEUROCRINE BIOSCIENCES BOARD OF DIRECTORS AUTHORIZES $500
MILLION SHARE REPURCHASE PROGRAM
Source text: ID:nPn40SSL1a
Further company coverage: NBIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall